Our
Facilities
Our Facility
Eirgen Pharma's facilities are based in Waterford, Ireland - a location that offers strategic access to both European and US markets. Our campus spans 40,000ft² of dedicated manufacturing space, with an additional 3,500m² high-containment expansion underway, set to be fully operational by late 2025. ​
Pharmaceutical Manufacturing That Grows With You
Our state-of-the-art facilities are purpose-designed for high-potency and non-potent oral solid doses - with ISO 14644 Class 8 cleanrooms, HEPA filtration, and cascading pressure zones for maximum containment.
​
Humidity-controlled suites, isolators, and OEB 4 solutions ensure safety at every step.
​
We manufacture film-coated tablets, softgels, and hard-shell capsules - from clinical to commercial scale.
​
Experts in HPAPIs, including cytotoxic and genotoxic compounds, we manage tech transfer, validation, packaging, and serialization with precision.
​
Safety and compliance are embedded in every detail - from PPE to real-time monitoring.
40,000ft dedicated Hi-Potency Facility
2
Low Humidity capability (<30%RH)
ISO 14644 Class 8 Clean-room Standard
Full body Air-Suit Capability
Single-pass double HEPA filtered air
Fully-equipped Analytical Labs
Fully Segregated Processing Rooms
Equipment to support Oral Solid Dose Manufacture & Packaging
Integrated R&D and Analytical Services
Innovation lies at the heart of our operations. Our on-site research and development laboratories are home to over 50 scientists working across formulation, analytical development, and regulatory support. We offer end-to-end services, including;
​
-
Formulation Development (immediate- and extended-release)
-
Analytical method development and validation
-
ICH stability testing
-
CMC documentation and regulatory filing support
​
This seamless integration between R&D and manufacturing ensures speed, efficiency, and quality throughout your product's lifecycle.
Looking to the future, Eirgen's ​3,500m² facility expansion is a significant step forward. Scheduled for commercialization in Q3 2025, the expansion includes the addition of high-containment manufacturing suites, enhanced blending, granulation, and tableting capabilities, and increased flexibility for both small and large batch sizes.
This new facility is designed to accommodate accelerated tech transfers, complex formulation requirements, and the next generation of high-potency therapies, with an aim to be at 1.02 billion capacity in 2027.
Our New Facility. Your Competitive
Edge.
Why Partner With Eirgen?
Eirgen Pharma is a trusted CDMO partner delivering speed, quality, and reliability across every phase of oral solid dose development and manufacturing. ​
​
-
High-Potency Expertise - Specialists in HP OSD formulation and scale-up
-
Agile & Fast - Flexible operations that adapt quickly to your project needs and timelines
-
Advanced Infrastructure - Containment and cleanroom technologies built for compliance
-
Regulatory Excellence - Proven track record with FDA, EMA, and global agencies
-
Strategic Location - EU-based with global supply chain reach
​